scout
Commentary|Articles|December 12, 2014

Toxicities Associated With PI3K Inhibitors

Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.

Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.

<<<

Go back to the SABCS conference page

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME